Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol "GRDX"
RBGPF
0.1000
The Fort Worth Press - Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol "GRDX"
USD
-
AED 3.672505
AFN 64.999617
ALL 81.873378
AMD 378.439629
ANG 1.79008
AOA 917.000017
ARS 1444.993898
AUD 1.424623
AWG 1.8025
AZN 1.698328
BAM 1.658498
BBD 2.01317
BDT 122.152876
BGN 1.67937
BHD 0.37697
BIF 2962.5
BMD 1
BND 1.270543
BOB 6.906845
BRL 5.239098
BSD 0.999546
BTN 90.307481
BWP 13.806116
BYN 2.86383
BYR 19600
BZD 2.010235
CAD 1.36445
CDF 2199.999975
CHF 0.776105
CLF 0.021794
CLP 860.539972
CNY 6.938197
CNH 6.93502
COP 3646.93
CRC 496.408795
CUC 1
CUP 26.5
CVE 93.750278
CZK 20.60345
DJF 177.720253
DKK 6.32319
DOP 63.000254
DZD 129.900254
EGP 47.009197
ERN 15
ETB 155.042675
EUR 0.846625
FJD 2.198801
FKP 0.732491
GBP 0.730199
GEL 2.695012
GGP 0.732491
GHS 10.944975
GIP 0.732491
GMD 73.000094
GNF 8753.999774
GTQ 7.666672
GYD 209.120397
HKD 7.813115
HNL 26.408086
HRK 6.376701
HTG 131.107644
HUF 322.478502
IDR 16766
ILS 3.082015
IMP 0.732491
INR 90.36925
IQD 1309.380459
IRR 42125.000158
ISK 122.749952
JEP 0.732491
JMD 156.640605
JOD 0.709028
JPY 155.879497
KES 129.000415
KGS 87.449822
KHR 4081.504905
KMF 417.999853
KPW 899.987247
KRW 1450.779878
KWD 0.30715
KYD 0.83298
KZT 501.119346
LAK 21499.832523
LBP 89508.041026
LKR 309.380459
LRD 185.911623
LSL 16.009531
LTL 2.95274
LVL 0.60489
LYD 6.319217
MAD 9.168716
MDL 16.926717
MGA 4429.877932
MKD 52.189044
MMK 2100.119929
MNT 3568.429082
MOP 8.04357
MRU 39.901294
MUR 45.890045
MVR 15.450054
MWK 1733.257012
MXN 17.245898
MYR 3.932499
MZN 63.750319
NAD 16.009531
NGN 1391.85959
NIO 36.785781
NOK 9.627875
NPR 144.492309
NZD 1.656195
OMR 0.384498
PAB 0.999521
PEN 3.364907
PGK 4.282347
PHP 59.040236
PKR 279.545138
PLN 3.57644
PYG 6631.277242
QAR 3.634567
RON 4.313702
RSD 99.384049
RUB 76.999691
RWF 1458.783824
SAR 3.750106
SBD 8.058101
SCR 13.748799
SDG 601.49205
SEK 8.90851
SGD 1.270205
SHP 0.750259
SLE 24.475005
SLL 20969.499267
SOS 570.272883
SRD 38.114499
STD 20697.981008
STN 20.775741
SVC 8.746163
SYP 11059.574895
SZL 16.015332
THB 31.639928
TJS 9.340767
TMT 3.51
TND 2.890372
TOP 2.40776
TRY 43.496603
TTD 6.770319
TWD 31.588801
TZS 2584.040204
UAH 43.256279
UGX 3563.251531
UYU 38.49872
UZS 12236.487289
VES 371.640565
VND 26002
VUV 119.537583
WST 2.726316
XAF 556.244594
XAG 0.011767
XAU 0.000201
XCD 2.70255
XCG 1.801384
XDR 0.691072
XOF 556.244594
XPF 101.131218
YER 238.374992
ZAR 15.96902
ZMK 9001.202602
ZMW 19.615608
ZWL 321.999592
- Britain's ex-prince Andrew leaves Windsor home: BBC
- Coach plots first South Africa World Cup win after Test triumph
- Spin-heavy Pakistan hit form, but India boycott risks early T20 exit
- Japan eyes Premier League parity by aligning calendar with Europe
- Whack-a-mole: US academic fights to purge his AI deepfakes
- Love in a time of war for journalist and activist in new documentary
- 'Unprecedented mass killing': NGOs battle to quantify Iran crackdown scale
- Seahawks kid Cooper Kupp seeks new Super Bowl memories
- Thousands of Venezuelans march to demand Maduro's release
- AI, manipulated images falsely link some US politicians with Epstein
Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol "GRDX"
BOCA RATON, FL / ACCESS Newswire / November 28, 2025 / Entero Therapeutics, Inc. (NASDAQ:ENTO) (the "Company") today announced that it will change its name to GridAI Technologies Corp., effective at 12:01 Eastern Time on Monday, December 1, 2025. The name change closely aligns the Company's business following its acquisition of 100% of GRID AI Corp ("GRID AI"), a grid-edge, AI-driven software and controls platform that enables utilities, retail energy providers, and large power users to dynamically manage load and distributed energy resources including battery energy storage systems. In connection with the name change, the Company will change its ticker symbol to "GRDX". The Company's common stock will commence trading on the Nasdaq Capital Market exchange under the new name and trading symbol on December 1, 2025.
"This marks the beginning of a new chapter for the business," said Jason Sawyer, Interim Chief Executive Officer of GridAI Technologies Corp. "Our mission is to enhance grid-edge intelligence using AI, machine learning and edge analytics by orchestrating supply and demand in real time, creating a more reliable, resilient, and transactive grid -now supported with our public-company platform - and this name change reflects that commitment."
The name and future ticker change do not affect the Company's legal structure, business operations, or existing financial reporting obligations. Shareholders are not required to take any action in connection with the change.
Further updates will be provided via regular press releases and regulatory filings.
About Entero Therapeutics, Inc. (NASDAQ:ENTO)
Entero Therapeutics, Inc. is a publicly listed company on Nasdaq. The Company is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company's programs address significant unmet needs in GI health and comprise development of Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. Following completion of the GRID AI acquisition, the Company intends to continue these prior operations and to also operate GRID AI as a wholly owned subsidiary and pursue opportunities at the intersection of AI and energy infrastructure.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding strategic benefits of the acquisition, market opportunities, product capabilities, stockholder approval of the transaction, Nasdaq's approval of an initial listing application, if any, and future operating results. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Important factors include, among others, our business strategy; the risk that regulatory or third-party approvals are delayed or not obtained; integration challenges; market adoption; competitive dynamics; macroeconomic and energy-market conditions; and other risks detailed from time to time in the Company's SEC filings. The Company undertakes no obligation to update forward-looking statements.
Investor & Media Contacts:
Entero Investor Relations
[email protected]
SOURCE: Entero Therapeutics, Inc.
View the original press release on ACCESS Newswire
H.M.Hernandez--TFWP
